SAG1

SAG1 (P30/SRS29B) is a GPI-anchored, tachyzoite-specific surface antigen of Toxoplasma gondii that functions as an adhesin mediating parasite attachment to host cells (PMID:3183382, PMID:8050521). Encoded by a single-copy, intron-free gene, its primary product carries an N-terminal signal sequence and a C-terminal hydrophobic tail directing GPI anchor attachment, confirmed biochemically by PI-PLC sensitivity and cross-reacting-determinant detection (PMID:3183382, PMID:9784539). The mature protein forms a homodimer whose interface generates a deep groove lined with positively charged residues proposed to engage sulfated glycoconjugates on target cells (PMID:12091874). Consistent with an adhesin role, anti-SAG1 antibodies and Fab fragments inhibit tachyzoite attachment and invasion, SAG1-deficient mutants bind host cells less efficiently, and a glucosamide neoglycoprotein competitively blocks infection of SAG1-positive parasites (PMID:7682587, PMID:8050521, PMID:8690540). CRISPR knockout confirms that SAG1 is specifically required for attachment and fitness in IFN-gamma-stimulated host cells and implicates host-cell surface sialic acids as attachment determinants under immune pressure (PMID:40607979); SAG1 itself does not bind heparin, distinguishing its ligand preference from the HSPG-binding SAG3 (PMID:11463464). SAG1 is expressed exclusively by tachyzoites and lost during bradyzoite and enteric-stage differentiation (PMID:7690809, PMID:7684705, PMID:15003495); this stage-specific downregulation is functionally essential, since forced SAG1 expression in bradyzoites drives excessive inflammatory cytokine responses and disrupts persistence (PMID:15944311). Its promoter contains upstream repeat elements required for accurate transcription initiation (PMID:7799972), and its expression is heterogeneous among tachyzoites and controlled by the transcription factor AP2IX-1 (PMID:40607979). At the surface-coat level, the SAG1/SAG2A surface antigens modulate acute virulence, with SRS29C acting as a negative regulator (PMID:23149485).

1. 1988 High

   Establishing the primary structure and predicted membrane topology of SAG1 defined it as a GPI-anchored surface protein, providing the molecular starting point for all subsequent functional work.

   Evidence cDNA/cosmid cloning and sequence analysis with beta-galactosidase fusion expression validated by anti-P30 monoclonal antibodies in RH

   PMID:3183382

   Open questions at the time

   • Sequence-based GPI prediction not yet biochemically confirmed at this stage
   • No structural or ligand information
2. 1993 High

   Antibody neutralization and mutant-parasite experiments first assigned SAG1 a functional role in host-cell invasion and implicated a glycosylated host receptor, moving it beyond a mere serological marker.

   Evidence in vitro invasion/neutralization assays with mAbs, Fab fragments, a P30-deficient mutant, and competitive neoglycoprotein inhibition in RH and PTg

   PMID:7682587

   Open questions at the time

   • Host receptor identity not defined
   • Attachment vs. later invasion steps not distinguished
3. 1993 Medium

   Localization and stage-expression studies established SAG1 as a tachyzoite-restricted surface antigen absent from the vacuolar network, tying its expression to parasite stage identity.

   Evidence IFA/immunoEM localization and in vivo mRNA/protein expression during reactivation and differentiation across ME-49 and differentiating strains

   PMID:8415546 PMID:7690809 PMID:7684705

   Open questions at the time

   • Transcriptional basis of stage restriction not yet defined
   • Functional consequence of stage-specific loss unknown
4. 1994 High

   Quantitative binding assays resolved SAG1's role to the attachment step specifically, distinguishing adhesion from downstream invasion events.

   Evidence radioisotope competitive binding to fixed fibroblasts with mAb/Fab inhibition and SAG1-defective mutant comparison

   PMID:8050521

   Open questions at the time

   • Residual attachment in mutants shows SAG1 is not the sole adhesin
   • Molecular ligand still unidentified
5. 1994 Medium

   Adoptive transfer of a SAG1-specific CD8+ T cell clone established that SAG1 is an immunologically protective antigen acting through an IFN-gamma-dependent effector mechanism, linking the surface antigen to host immunity.

   Evidence adoptive transfer of a SAG1-specific CD8+ T cell clone with CD4 depletion and anti-IFN-gamma neutralization in mice

   PMID:7907106

   Open questions at the time

   • Does not address SAG1's cell-biological function
   • Epitope and antigen-processing details not defined
6. 1995 High

   Promoter dissection identified upstream repeat elements governing accurate and efficient SAG1 transcription initiation, opening the mechanism of its regulated expression.

   Evidence promoter deletion constructs transfected into Toxoplasma with transcription-initiation analysis

   PMID:7799972

   Open questions at the time

   • Trans-acting factors not identified
   • Does not explain tachyzoite-specific restriction
7. 1998 Medium

   Biochemical and comparative analyses confirmed the GPI anchor experimentally and revealed a conserved cysteine/domain topology shared with the Neospora homolog, supporting a conserved fold and function.

   Evidence surface biotinylation, PI-PLC cleavage, anti-CRD immunoblotting, and sequence comparison in N. caninum

   PMID:9784539

   Open questions at the time

   • Functional conservation inferred from sequence, not tested
   • Cross-species work is on the Neospora homolog
8. 2002 High

   The 1.7 A crystal structure defined SAG1 as a homodimer forming a basic groove, providing a structural model for how it might engage negatively charged host-cell surface ligands.

   Evidence X-ray crystallography and homodimer interface analysis

   PMID:12091874

   Open questions at the time

   • Ligand in the groove not co-crystallized
   • Groove specificity for a defined glycoconjugate not proven structurally
9. 2001 High

   Recombinant binding assays showed SAG1 does not bind heparin/HSPG, refining its ligand specificity and assigning HSPG-mediated attachment to the paralog SAG3 rather than SAG1.

   Evidence heparin-binding and CHO/HSPG-deficient adhesion assays with recombinant SAG1 and SAG3

   PMID:11463464

   Open questions at the time

   • Positive ligand for SAG1 still undefined
   • Reconciliation with the basic-groove model deferred
10. 2002 Medium

    Chimera and toxin studies used SAG1's transmembrane/GPI features as tools, showing its cytoplasmic tail lacks microneme-targeting information and that its GPI anchor makes it a target of GPI-directed toxins.

    Evidence SAG1/MIC chimeric targeting and cleavage assays, and Clostridium septicum alpha-toxin binding with ultrastructural analysis in RH and P strains

    PMID:10982850 PMID:11927542 PMID:12117945 PMID:9657336

    Open questions at the time

    • Trafficking determinants of native SAG1 not fully mapped
    • Strain differences in toxin binding not mechanistically explained
11. 2005 High

    Forced bradyzoite-stage expression showed that stage-specific SAG1 downregulation is functionally required for persistence, establishing a causal link between regulated antigen expression and immune-mediated control.

    Evidence transgenic constitutive SAG1 expression in bradyzoites with in vivo cyst counting, cytokine measurement, and histopathology

    PMID:15944311

    Open questions at the time

    • Mechanism by which SAG1 provokes the cytokine response unclear
    • Direct target of the induced immune response not defined
12. 2004 High

    A comprehensive in vivo stage-marker survey confirmed SAG1 is confined to tachyzoites and lost during bradyzoite and enteric-stage conversion, with intermediate co-expression states.

    Evidence in vivo immunocytochemistry with a stage-specific marker panel and electron microscopy in mouse and cat tissues

    PMID:15003495

    Open questions at the time

    • Regulatory logic of the switch not resolved here
13. 2012 High

    Genetic deletion and overexpression placed SAG1 within a surface-coat system that modulates acute virulence, identifying SRS29C as a negative regulator uncovered upon SAG1/SAG2A loss.

    Evidence targeted sag1/sag2A deletion, transgenic SRS29C overexpression, and mouse acute virulence assays in RH

    PMID:23149485

    Open questions at the time

    • Whether virulence effect is due to SAG1 loss per se or coat remodeling not separated
    • Molecular mechanism of SRS29C-mediated attenuation unknown
14. 2020 Medium

    Single-cell transcriptomics revealed heterogeneous, sporadic SAG1 expression among tachyzoites and identified AP2IX-1 as a transcription factor controlling the switch between ubiquitous SAG1 and rare surface antigens.

    Evidence scRNA-seq of >5,400 tachyzoites/bradyzoites across three strains with computational TF identification

    PMID:32065584

    Open questions at the time

    • AP2IX-1 regulation of SAG1 is largely correlative here
    • Functional significance of expression heterogeneity unresolved
15. 2025 High

    CRISPR knockout demonstrated a context-specific requirement for SAG1 in attachment and fitness under IFN-gamma stimulation and implicated host sialic acids as attachment determinants, resolving the ligand class SAG1 exploits under immune pressure.

    Evidence CRISPR/Cas9 SAG1 knockout with IFN-gamma fitness and attachment assays plus sialic acid perturbation

    PMID:40607979

    Open questions at the time

    • Direct SAG1-sialic acid binding not structurally demonstrated
    • Why the requirement is exacerbated by IFN-gamma not mechanistically defined

• The precise host-cell ligand engaged by the SAG1 basic groove and the mechanism reconciling its non-heparin, sialic-acid-linked adhesion with the structural model remain undefined.
• No co-structure of SAG1 with a host ligand
• Mechanistic basis of IFN-gamma-specific fitness requirement unknown
• Direct link between AP2IX-1 and SAG1 promoter elements not established